The Study of Molecular Risk Panels (70-gene Assay) in Chinese Breast Cancer Patients



Status:Recruiting
Healthy:No
Age Range:18 - 70
Updated:4/21/2016
Start Date:November 2015
End Date:November 2017
Contact:Sarah Untch
Phone:(412) 770-6906

Use our guide to learn which trials are right for you!

The Study of Molecular Risk Panels in Chinese Breast Cancer Patient Using Mammaprint, TargetPrint, BluePrint and Research Gene Panel Assays.

This study is experimental and will prospectively assess the proportion of patients in the
two (2) MammaPrint Risk categories in patients of Chinese descent.

The incidence of breast cancer in Chinese women is lower than that of a Western population.
Breast cancer is the most common cancer in Chinese women and the incidence is rising.
Moreover there are more premenopausal women with breast cancer where the breast cancer
incidence peaks in the forties and the postmenopausal rise in incidence is less commonly
seen. As the genetic predisposition to breast cancer is increasingly understood, it has been
suggested that the differences in breast cancer incidence in different ethnic populations is
potentially due to interactions between lifestyle and genetic characteristics. To date, the
use of Agendia's gene expression assays in Chinese women has not been studied. In this
study, the feasibility of the gene-expression prognostic assays for risk assessment in this
specific group will be assessed. Moreover, the specific molecular characteristics and
potential biomarkers will be studied, focusing especially on the large group of
premenopausal breast cancer patients.

Inclusion Criteria:

- Females aged 18 year to 70 year,

- diagnosis of Stage I or Stage II (excluding those involving more than 3 lymph nodes)
Breast Cancer

- Chinese descent

Exclusion Criteria:

- Stage II Breast Cancer with more than 3 positive lymph nodes
We found this trial at
1
site
630 W 168th St
New York, New York
212-305-2862
Principal Investigator: Margaret Chen-Seetoo, MD
Columbia University Medical Center Situated on a 20-acre campus in Northern Manhattan and accounting for...
?
mi
from
New York, NY
Click here to add this to my saved trials